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despite the advent of tyrosine kinase inhibitors,4 this
complication should be added to future reviews of this
rapidly moving field.
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provide additional examples of chemotherapy-induced throm-
botic microangiopathy (TMA). We thank these authors for
reviewing the possible role of the above chemotherapeutic
agents in the development of TMA. Both interferon-a3
and -b4,5 have been associated with TMA. However, the
mechanism by which interferon-a and -b could induce TMA
lesions remains unclear. Drugs such as interferon might
disrupt complex pathways of complement regulation and have
a role in endothelial damage.3 In recent years, mutations of
complement system regulators have been directly impli-
cated in the induction of atypical hemolytic uremic
syndrome.6 It is possible that alteration of alternate pathway
of the complement system might be involved in many such
cases of chemotherapy-induced TMA. We thank Shavit and
colleagues7 to bring to our attention their previously
reported case series on renal TMA seen following pegylated
liposomal doxorubicin (PLD) use. While PLD was implicated
as a cause of the renal TMA in the three cases reported by
these authors,7 two of the three patients had also received
either bevacizumab or gemcitabine. Bevacizumab and gemci-
tabine, as noted in our review,8 have also been associated
with renal TMA. Nevertheless, anthracycline therapy is
widely used in many cancer treatments and knowledge of
both glomerular epithelial9 and endothelial damage7 by such
agents is useful to the onco-nephrologist. In addition, since
the writing of our review,8 other novel chemotherapeutic
agents have also been associated with glomerular disease.
Sasaki et al.10 report a case of diffuse proliferative immuno-
globulin A–dominant immune complex glomerulonephritis
in a patient who received cetuximab for recurrent oral
squamous cell carcinoma. In this case, the authors make note
of the rapid recovery of kidney function within 3 weeks of
discontinuing the drug. This case suggests the need for
monitoring kidney function in patients being treated with
recently developed monoclonal antibodies. Finally, a recent
letter to the editor suggested an association of lenolilo-
mide (anti–multiple myeloma agent) with minimal change
disease.11 As the field of oncology is rapidly growing, both
oncologists and nephrologists will need to be vigilant for any
glomerular nephrotoxicities that might occur following the
use of novel chemotherapeutic agents.
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A hip fracture in a dialysis patient
with Ab2M amyloidosis
To the Editor: We read the case report presented by Bataille
et al.1 with great interest. In Japan, the number of patients
whose dialysis vintage is more than 25 years reached 12,293 at
the end of 2012. Although the number of operative cases of
carpal tunnel syndrome is declining, Ab2M amyloidosis is
still a common disease among long-term hemodialysis
patients. For instance, there are about 100 patients whose
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